Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Last updated: February 6, 2024
Sponsor: Center Eugene Marquis
Overall Status: Trial Not Available

Phase

N/A

Condition

Brain Cancer

Brain Tumor

Neurofibromatosis

Treatment

[18F]DPA-714

Clinical Study ID

NCT05672082
2022-1-58-002
  • Ages > 18
  • All Genders

Study Summary

The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are [18F]DPA-714 and 18F-GE180. We hypothesize that [18F]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age greater than or equal to 18 years
  • Suspicion of an operable diffuse glioma
  • Written informed consent (signed)
  • Affiliated or beneficiary of a social security plan

Exclusion

Exclusion Criteria:

  • Suspicion of grade I glioma
  • Surgical urgency (less than 8 days between the suspected diagnosis and surgery)
  • Pregnant or breastfeeding woman
  • Persons deprived of liberty or under guardianship
  • Impossibility to undergo the medical follow-up of the trial for geographical, socialor psychological reasons

Study Design

Treatment Group(s): 1
Primary Treatment: [18F]DPA-714
Phase:
Study Start date:
October 01, 2023
Estimated Completion Date:
April 01, 2025